Abstract: Compounds and compositions that are useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or conditions, such as cancers, autoimmune diseases, allergic diseases, inflammatory diseases, fibrosis, metabolic disorders, and neurodegenerative diseases.
Abstract: Provided is an azacycloalkylcarbonyl cyclic amine compound which is useful as an active ingredient in a pharmaceutical composition for a treatment of a neutrophil associated inflammatory disease. The azacycloalkylcarbonyl cyclic amine compound of the present invention is a compound of Formula (I) or a salt thereof. (in the formula, Ring A represents azacycloalkyl which may have a substituent and may be spiro-fused; Y represents alkyl which may have a substituent, cycloalkyl which may have a substituent, or the like; L represents a nitrogen-containing aromatic heterocycle or the like; Z represents cycloalkyl which may have a substituent, an aromatic hydrocarbon ring which may have a substituent, a non-aromatic heterocycle which may have a substituent, or the like; and m and n each independently represent an integer of 1 or 2.
Type:
Grant
Filed:
December 5, 2024
Date of Patent:
January 13, 2026
Assignees:
Alivexis, Inc., Astellas Pharma Inc.
Inventors:
Takafumi Shimizu, Yoh Terada, Takeo Urakami, William Sinko, Jun Maeda, Tsubasa Watanabe, Hiroaki Yamagishi